2 1 Shi Ji Jing Ji Bao Dao·2025-05-28 02:30Group 1 - The A-share market showed mixed performance on May 28, with the Sci-Tech Innovation Pharmaceutical Index ETF (588700) down 0.21% and a trading volume exceeding 8 million yuan [1] - The Sci-Tech Innovation Pharmaceutical Index ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which includes 50 large-cap companies in biopharmaceuticals, biomedical engineering, and related sectors [1] - Recent data from the American Society of Clinical Oncology (ASCO) annual meeting highlighted that Chinese experts had a record number of presentations, with 71 original research results showcased, indicating a strong international presence for Chinese innovative drugs [1] Group 2 - CITIC Securities expressed strong confidence in a reversal trend for the pharmaceutical sector in 2025, emphasizing innovative drugs and the recovery of left-behind sectors as key investment opportunities [2] - Zhongtai Securities noted that the Chinese innovative drug industry is transitioning from a phase of capital bubble to a stage of genuine achievements, with increasing recognition from multinational corporations [2] - The recommendation includes actively embracing the pharmaceutical sector and exploring opportunities in AI healthcare and related fields, as well as sub-industries and individual stocks experiencing recovery [2]